Cogent Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost, Current
Cogent Biosciences, Inc. (COGT) had Debt Securities, Available-for-sale, Amortized Cost, Current of $59.55 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2023-05-09
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $59.55M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $119.49M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $148.69M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2023-03-31 | $59.55M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $119.49M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $148.69M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |